Publications by authors named "Mariel C Duurland"
Article Synopsis
- Methotrexate (MTX) is a common medicine for rheumatoid arthritis, but it may affect how well people’s immune systems respond to vaccines and infections.
- In a study, researchers looked at how MTX treatment affected immune responses in patients who received a COVID-19 vaccine compared to healthy people and others not on MTX.
- They found that while many immune cells were similar between patients and controls, those on MTX had fewer activated CD4 T cells, leading to slower antibody responses after vaccination.
T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination.
J Neurol Neurosurg Psychiatry
August 2024
Article Synopsis
- mRNA vaccines effectively protect against SARS-CoV-2 in healthy individuals, but their effectiveness in multiple sclerosis (MS) patients treated with ocrelizumab (OCR) is unclear.
- A study found that 63% of OCR-treated MS patients did not produce detectable antibodies after vaccination, and they showed lower antibody responses compared to healthy subjects.
- The research suggests that scheduling vaccinations carefully for OCR-treated patients can improve their immune responses, highlighting potential markers (CD38 and HLA-DR) for assessing vaccine efficacy in these patients.
γδ T cells are important components of the immune system due to their ability to elicit a fast and strong response against infected and transformed cells. Because they can specifically and effectively kill target cells in an MHC independent fashion, there is great interest to utilize these cells in anti-tumor therapies where antigen presentation may be hampered. Since only a small fraction of T cells in the blood or tumor tissue are γδ T cells, they require extensive expansion to allow for fundamental, preclinical and research.
View Article and Find Full Text PDFArticle Synopsis
- SARS-CoV-2-specific CD8 T cells play a crucial role in protecting against viral variants and reducing disease severity, especially in patients lacking cross-reactive antibodies.
- mRNA vaccines elicit strong immune responses, but the effectiveness among patients with chronic immune-mediated inflammatory disorders (IMIDs), particularly those on TNF inhibitors (TNFi), is less understood.
- Analysis revealed that both TNFi-treated and untreated inflammatory bowel disease (IBD) patients generate strong spike-specific CD8 T cell responses after mRNA vaccination, comparable to healthy individuals, indicating that vaccination is beneficial regardless of treatment status.
Background: CD11cTbet B cells are enriched in autoimmunity and chronic infections and also expand on immune challenge in healthy individuals. CD11cTbet B cells remain an enigmatic B-cell population because of their intrinsic heterogeneity.
Objectives: We investigated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen-specific development and differentiation properties of 3 separate CD11c B-cell subsets-age-associated B cells (ABCs), double-negative 2 (DN2) B cells, and activated naive B cells-and compared them to their canonical CD11c counterparts.
Objectives: High-magnitude CD8 T cell responses are associated with mild COVID-19 disease; however, the underlying characteristics that define CD8 T cell-mediated protection are not well understood. The antigenic breadth and the immunodominance hierarchies of epitope-specific CD8 T cells remain largely unexplored and are essential for the development of next-generation broad-protective vaccines. This study identified a broad spectrum of conserved SARS-CoV-2 CD8 T cell epitopes and defined their respective immunodominance and phenotypic profiles following SARS-CoV-2 infection.
View Article and Find Full Text PDF